膀胱内灌注丝裂霉素与表柔比星预防膀胱癌术后复发的临床研究  

Clinical trial of epirubicin vs mitomycin bladder instillation chemotherapy for the treatment of superficial bladder cancer

作　　者：李美凤[1] 周小庆[1] 曾菁[1] 罗松涛[2] 

机构地区：[1]丽水市人民医院泌尿外科,浙江丽水323000 [2]泸州医学院附属中医医院外科,四川泸州646000

出　　处：《中国临床药理学杂志》2014年第6期500-502,共3页The Chinese Journal of Clinical Pharmacology

基　　金：泸州医学院-泸州医学院附属中医医院联合科研基金资助项目

摘　　要：目的评价丝裂霉素与表柔比星浅表性膀胱灌癌(SBC)术后灌注化疗疗效及安全性。方法对2011-04—2013-01收治的SBC术后患者78例进行回顾分析,术后丝裂霉素膀胱灌注化疗者31例,灌注表柔比星者47例,比较2组灌注化疗的疗效及不良反应。结果丝裂霉素组,术后中位随访12.6个月,随访期间肿瘤复发率为16.1%(5/31);表柔比星组,随访13.2个月,复发率为14.7%(7/47),2组复发风险比较(HR=1.02)差别无统计学意义(P>0.05)。丝裂霉素组与表柔比星组局部药物不良反应发生率分别为54.8%(17/31),57.4%(27/47),差别无统计学意义(P>0.05)。结论丝裂霉素与表柔比星用于SBC术后灌注化疗疗效及安全性无明显差别。Objective To evaluate the clinical efficacy and adverce drug reaction （ADR） for epirubicin and mitomycin bladder instillation chemotherapy in the treatment of superficial bladder cancer （SBC）. Methods Seventy - eight cases of postsurgical SBC recruited from Apr 2011 to Jan 2013 in our hospital retrospectively. Of the 78 subjects, 31 patients were treated by mitomycin and other 47 eases were treated by epirubicin. The clinical efficacy and ADR of the two groups were recorded and compared. Results The median follow -up period of mitomycin group was 12.6 months with a recurrence rate of 16. 1% （5/31）. And the median follow - up period of epirubicin group was 13.2 months with a recurrence rate of 14. 7% （7/47）. No statistical difference of recurrence of hazard ratio （ HR = 1.02） was found between the two groups （ P 〉 0. 05 ）. Conclusion There were no statistical difference for epirubicin and mitomycin bladder instillation chemotherapy in the treatment of superficial bladder cancer.

关 键 词：丝裂霉素 表柔比星 膀胱癌 灌注化疗 随访 

分 类 号：R737.14[医药卫生—肿瘤] R979.1[医药卫生—临床医学]